Influenza

High-Dose Quadrivalent Influenza Vaccine Shows Superior Immunogenicity in Young Children

HEC116094 Shows Potent Activity as PB2 Inhibitor Against Influenza A Virus

HEC116094 demonstrates potent in vitro and in vivo activity against influenza A virus, outperforming existing therapies.

Cost-Effectiveness of Adjuvanted Influenza Vaccine in Older Adults in the Netherlands

Replacing the standard influenza vaccine with the adjuvanted version in older adults could save €4.3-12.8 million and gain 2,220-6,659 QALYs.

FDA Approves First Generic of Xofluza for Influenza Treatment

The FDA has approved the first generic version of Xofluza, a single-dose treatment for influenza.

GSK's AS03-adjuvanted H5N8 vaccine shows promising immunogenicity and safety in Phase 1/2 trial

The Phase 1/2 trial demonstrated that GSK's AS03-adjuvanted H5N8 vaccine met FDA immunogenicity criteria, with higher immune responses in younger adults.